【摘要】：正近20年來(lái),多重耐藥革蘭陰性細(xì)菌(MDRGNR)在全球范圍內(nèi)呈蔓延趨勢(shì),嚴(yán)重威脅動(dòng)物及人類(lèi)健康;又由于缺乏新的、較為有效的抗生素,使得多黏菌素類(lèi)(包括多黏菌素B及黏菌素)藥物在臨床又重新得到重視和應(yīng)用,并成為治療MDRGNR感染的最佳選擇,甚至是最后的防線~([1])。腎毒性是多黏菌素的主要臨床副作用之一,發(fā)生率高達(dá)60%~([1,2])。越來(lái)越多的證據(jù)表明,當(dāng)前臨床推薦的
[Abstract]:In the past 20 years, the multidrug resistant gram-negative bacteria (MDRGNR) have been spreading all over the world, which is a serious threat to animal and human health. Due to the lack of new and effective antibiotics, polymyxins (including polymyxin B and myxin B) have been paid more attention and applied in clinic, and become the best choice for the treatment of MDRGNR infection. Even the last line of defense. Nephrotoxicity is one of the main clinical side effects of polymyxin. There is growing evidence that the current clinical recommendations
【作者單位】： 中國(guó)農(nóng)業(yè)大學(xué)動(dòng)物醫(yī)學(xué)院;
【基金】：國(guó)家科技支撐計(jì)劃(2015BAD11B03)
【分類(lèi)號(hào)】：R96;S859.7
，

本文編號(hào)：2367194